Skip to Content


Active Substance: trovafloxacin
Common Name: trovafloxacin
ATC Code: J01MA13
Marketing Authorisation Holder: Pfizer Limited
Active Substance: trovafloxacin
Status: Withdrawn
Authorisation Date: 1998-07-08
Therapeutic Area: Bacterial Infections
Pharmacotherapeutic Group: Antibacterials for systemic use

Therapeutic Indication

Trovafloxacin is a synthetic broad spectrum quinolone antibacterial agent indicated for the treatment of the following infections in adults:

  • Pneumonia: Community Acquired Pneumonia and Nosocomial Pneumonia (mild, moderate, and severe).

Note: Efficacy in patients with very severe nosocomial pneumonia and in particular infections due to less susceptible pathogens e.g. P. aeruginosa, has not been established. See also section 4.2.

  • Acute Exacerbations of Chronic Bronchitis
  • Acute Sinusitis
  • Complicated Intra-abdominal Infections and Acute Pelvic Infections
  • Salpingitis
  • Uncomplicated Gonococcal Urethritis and Cervicitis
  • Chlamydial Cervicitis
  • Complicated Skin and Soft Tissue Infections

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

The marketing authorisation for Turvel has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.